Doctors Revision

Anti-Vertigo Drugs: Pharmacology, Dosing and Rational Symptom Control

Text size
On this page

1 Overview

Vertigo is an illusion of movement — spinning, rocking or tilting — arising from imbalance between the paired vestibular inputs reaching the brain. Anti-vertigo drugs are symptomatic vestibular suppressants: they damp the abnormal vestibular signal or its central interpretation while the brain compensates. The central prescribing principle is short courses matched to the cause: long-term suppression is not benign — it blocks central compensation and prolongs disability. And in the commonest cause of all, BPPV, drugs are a second-class citizen — repositioning maneuvers are the treatment.

Angular acceleration detected in the semicircular canals
The semicircular canals detect angular acceleration; abnormal endolymph movement or dislodged otoliths create the asymmetric vestibular signal that anti-vertigo drugs work to suppress.

2 Learning Objectives

  • Explain how vestibular suppressants reduce vertigo, and why duration must be limited.
  • Differentiate peripheral from central vertigo at the bedside.
  • Compare the classes of anti-vertigo drugs — antihistamine/anticholinergics, betahistine, benzodiazepines, antiemetics, diuretics and corticosteroids — with doses and adverse effects.
  • Select rational drug–cause combinations for BPPV, vestibular neuritis, labyrinthitis and Ménière's disease.
  • Counsel safely in the elderly, pregnancy and patients with glaucoma/prostatism.

3 Physiological Rationale for the Drugs

Balance depends on symmetric resting activity of the two vestibular nuclei. When one labyrinth is injured (neuritis) or fires aberrantly (otolith in a canal), the nuclei become asymmetric and the brain interprets the mismatch as spinning — with the vestibulo-ocular reflex producing nystagmus, and vagal output producing nausea and vomiting. Anti-vertigo drugs act at three levels:

  • At the labyrinth — antihistamine/anticholinergic agents (meclizine, cinnarizine, scopolamine) reduce labyrinthine excitability and vestibular nuclei firing.
  • In the brainstem — benzodiazepines (diazepam, clonazepam) damp vestibular nuclear and cerebellar output through GABAA enhancement; histamine pathways at the vomiting centre are blocked by the same H1 agents.
  • At the emetic pathway — antiemetics (prochlorperazine, promethazine, metoclopramide, ondansetron) control nausea; promethazine and prochlorperazine add their own vestibular suppression.

Recovery comes not from drugs but from vestibular compensation — central recalibration that needs active exposure to movement. Chronic suppression prevents that learning and delays recovery.

4 Causes of Vertigo — Before the Prescription

Scroll the table sideways on a smaller screen.

FeaturePeripheral (inner ear/vestibular nerve)Central (brainstem/cerebellum)
Onset / severitySudden, intenseGradual, often milder but persistent
Nausea/vomitingMarkedVariable
NystagmusUnidirectional, horizontal-rotatory, fatigable, inhibited by fixationMultidirectional, vertical/purely vertical-torsional, non-fatigable, not inhibited by fixation
Hearing loss / tinnitusMay be present (Ménière's, labyrinthitis)Usually absent (but AICA strokes can)
Other signsNone neurologicalDiplopia, dysarthria, ataxia, weakness — posterior circulation stroke until proven otherwise
Common causesBPPV, vestibular neuritis, labyrinthitis, Ménière's diseaseStroke, TIA, vestibular migraine, cerebellar lesions, MS

Any central feature, new severe headache, or inability to walk mandates urgent neuroimaging — no anti-vertigo drug changes that.

5 Drug Classes in Detail

Antihistamine–anticholinergics (first-line vestibular suppressants)

  • Meclizine — the best-supported agent; H1 antagonist with central anticholinergic action at the vestibular nuclei, vomiting centre and CTZ. 25–100 mg/day in divided doses; onset ~1 hour. Indications: acute peripheral vertigo, Ménière's flares, motion sickness; useful short-term in BPPV while awaiting/repositioning. Sedating but among the better-tolerated; drug of choice in pregnancy. Avoid with alcohol and other sedatives.
  • Cinnarizine — H1 blocker plus calcium-channel inhibition of vestibular hair cells; widely used for vertigo and motion sickness (25 mg three times daily acutely, then taper). Sedation, weight gain, and extrapyramidal effects with chronic use.
  • Dimenhydrinate / diphenhydramine — effective but markedly sedating; useful when sedation is acceptable (e.g. severe acute neuritis with vomiting).
  • Scopolamine (hyoscine) — transdermal anticholinergic, best for motion sickness; avoid in glaucoma and prostatism.

Betahistine

An H3-antagonist/weak H1-agonist that increases vestibular nuclei excitability and inner-ear microcirculation — in effect it hastens compensation rather than suppressing, so it suits recurrent or residual symptoms (Ménière's, post-neuritis residual dizziness). Usual dose 16 mg three times daily, tapering to 8 mg bd maintenance; effect builds over weeks. Generally well tolerated (headache, GI upset). It does not help the acute spinning attack itself.

Benzodiazepines

Diazepam (2–5 mg), lorazepam, clonazepam suppress central vestibular pathways; reserved for severe acute vertigo with distressing anxiety or refractory symptoms, short course only. Habituation, falls in the elderly and impaired compensation are the costs; avoid chronic use.

Antiemetics

  • Prochlorperazine / promethazine — phenothiazines with their own vestibular-suppressant effect; the workhorses when vomiting dominates. Extrapyramidal effects, hypotension, anticholinergic burden — caution in the elderly.
  • Ondansetron — 5-HT3 antagonist; controls nausea without vestibular suppression or sedation; preferred when the patient must stay alert or in Parkinson disease (no dopamine blockade).
  • Metoclopramide — useful when nausea coexists with dysmotility; avoid in Parkinson disease (D2 blockade).

Cause-modifying drugs (not suppressants)

  • Diuretics — potassium-sparing (e.g. bendroflumethiazide or amiloride per protocol) for Ménière's disease, with low-salt diet.
  • Corticosteroids — early course in vestibular neuritis (e.g. prednisolone taper) may hasten recovery in severe loss.

6 Drug Monographs: Doses, Indications & Safety

Each anti-vertigo drug as a full monograph: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.

Meclizine (antihistamine–anticholinergic)

Scroll the table sideways on a smaller screen.

Meclizine — H1 antagonist with central anticholinergic action
MechanismBlocks H1 receptors and has central anticholinergic action at the vestibular nuclei, vomiting centre and chemoreceptor trigger zone
IndicationsAcute peripheral vertigo, Ménière's flares, motion sickness, BPPV symptom relief while awaiting repositioning; drug of choice for vertigo/nausea in pregnancy
Adult dose25–100 mg/day in divided doses (e.g. 25–50 mg 2–3 times daily); motion sickness: 25–50 mg 1 hour before travel
Paediatric dose>12 years: as adult; <12 years: not recommended
Adverse effectsDrowsiness, dry mouth, blurred vision, constipation, urinary retention; generally among the best-tolerated suppressants
ContraindicationsNarrow-angle glaucoma, urinary retention/prostatism (caution); caution with other sedatives
InteractionsAdditive sedation with alcohol, benzodiazepines, opioids and other CNS depressants; additive anticholinergics
Patient advice / monitoringCauses drowsiness — no driving until the response is known; use for days, not weeks; swallow whole with water; dry mouth — sips of water, sugar-free gum

Cinnarizine (antihistamine–calcium-channel blocker)

Scroll the table sideways on a smaller screen.

Cinnarizine — H1 blocker + vestibular calcium-channel inhibitor
MechanismBlocks H1 receptors and inhibits calcium influx into vestibular hair cells, reducing labyrinthine excitability
IndicationsVertigo of labyrinthine origin (neuritis, Ménière's), motion sickness, vestibular vertigo prophylaxis
Adult doseAcute vertigo: 30 mg 3 times daily, tapering to 15 mg 3 times daily as symptoms settle; motion sickness: 30 mg 2 hours before travel
Paediatric dose5–12 years: half the adult dose (15 mg 2–3 times daily); <5 years: not recommended
Adverse effectsSedation, weight gain, dry mouth, GI upset; extrapyramidal symptoms and depression with chronic use
ContraindicationsParkinson disease; caution in elderly, glaucoma, prostatism
InteractionsAdditive sedation with alcohol and CNS depressants; may enhance antihypertensives
Patient advice / monitoringTaper as symptoms improve; report involuntary movements or low mood on long courses; avoid alcohol; may impair driving

Betahistine (compensation facilitator)

Scroll the table sideways on a smaller screen.

Betahistine — H3 antagonist / weak H1 agonist
MechanismInhibits presynaptic H3 autoreceptors → increases histamine turnover and vestibular nuclei excitability; improves inner-ear microcirculation — facilitates compensation rather than suppressing the signal
IndicationsMénière's disease (recurrent attacks, tinnitus, hearing fluctuation); residual dizziness after vestibular neuritis; not for the acute spinning attack
Adult dose16 mg 3 times daily (max 48 mg/day); maintenance 8 mg twice daily; effect builds over weeks — take continuously
Paediatric doseNot established — specialist use only
Adverse effectsHeadache, GI upset, rash — generally very well tolerated
ContraindicationsPhaeochromocytoma; caution in asthma, peptic ulcer disease (histaminergic effect)
InteractionsAntihistamines (H1) may blunt its effect — avoid combining with meclizine concurrently; minimal other interactions
Patient advice / monitoringTake with food (reduces GI upset); expect benefit over weeks, not hours; continue through maintenance; report worsening asthma or ulcer symptoms

Prochlorperazine (phenothiazine antiemetic)

Scroll the table sideways on a smaller screen.

Prochlorperazine — D2 antagonist with vestibular suppression
MechanismBlocks dopamine D2 at the CTZ and has H1/anticholinergic actions that add vestibular suppression
IndicationsSevere vertigo with vomiting (acute neuritis, labyrinthitis, Ménière's attack); nausea and vomiting of other causes; labyrinthine disorders
Adult doseVertigo/nausea: 5 mg 3 times daily oral; acute: 12.5 mg IM or slow IV; antiemetic max 30 mg/day
Paediatric dose1–5 years: 2.5 mg twice daily; 6–12 years: 2.5–5 mg 2–3 times daily (short courses, specialist guidance)
Adverse effectsExtrapyramidal effects (acute dystonia, akathisia, parkinsonism), hypotension, sedation, anticholinergic effects; tardive dyskinesia with chronic use
ContraindicationsParkinson disease; caution in elderly, epilepsy, hepatic impairment, hypotension
InteractionsAdditive sedation and hypotension with alcohol, opioids, antihypertensives; anticholinergics compound EPS-adjacent effects; CYP2D6 inhibitors raise levels
Patient advice / monitoringShortest effective course; report stiffness, restlessness or involuntary movements immediately; rise slowly (postural hypotension); avoid driving

Ondansetron (5-HT3 antagonist)

Scroll the table sideways on a smaller screen.

Ondansetron — selective 5-HT3 receptor antagonist
MechanismBlocks 5-HT3 receptors in the gut and CTZ — controls nausea without vestibular suppression or sedation
IndicationsNausea/vomiting when the patient must stay alert; preferred antiemetic in Parkinson disease (no dopamine blockade); chemotherapy/radiotherapy-induced nausea
Adult dose8 mg 2–3 times daily oral; or 4–8 mg slow IV/IM 8-hourly
Paediatric dose0.15 mg/kg per dose (max 8 mg), 8-hourly
Adverse effectsHeadache, constipation, flushing; QT prolongation (caution with other QT drugs, electrolyte disturbance)
ContraindicationsCongenital long QT; caution with other QT-prolonging drugs and hypokalaemia/hypomagnesaemia
InteractionsQT-prolonging drugs (amiodarone, haloperidol, citalopram); serotonergic drugs (theoretical syndrome risk — large doses); CYP3A4/2D6 inhibitors raise levels
Patient advice / monitoringNo sedation — preferred when alertness matters; correct potassium/magnesium if depleted; report palpitations or fainting

Metoclopramide (prokinetic antiemetic)

Scroll the table sideways on a smaller screen.

Metoclopramide — D2 antagonist + prokinetic
MechanismBlocks D2 at CTZ and increases gastric motility — empties the stomach, reducing both nausea and reflux
IndicationsNausea/vomiting, especially with gastric stasis/dyspepsia; migraine-associated nausea; not for Parkinson patients
Adult dose10 mg 3 times daily, 30 minutes before meals; max 30 mg/day; limit to 5 days
Paediatric dose>1 year: 0.1 mg/kg per dose up to 3 times daily (max 0.5 mg/kg/day)
Adverse effectsDrowsiness, diarrhoea; extrapyramidal effects (dystonia, especially young women), hyperprolactinaemia; tardive dyskinesia with prolonged use
ContraindicationsParkinson disease, GI obstruction/perforation/bleeding, phaeochromocytoma, epilepsy (caution)
InteractionsOpioids and anticholinergics oppose its prokinetic effect; additive sedation; CYP2D6 inhibitors raise levels
Patient advice / monitoringTake before meals; stop after 5 days; report restlessness, stiffness or involuntary movements; avoid in children except specialist advice

Diazepam (vestibular suppressant, short course)

Scroll the table sideways on a smaller screen.

Diazepam — GABAA positive allosteric modulator
MechanismPotentiates GABAA inhibition in vestibular nuclei and cerebellar pathways, damping central vestibular output
IndicationsSevere acute vertigo with distressing anxiety, refractory symptoms — rescue use only, a few days at most
Adult dose2–5 mg 2–3 times daily for 1–3 days, then stop; avoid repeat courses
Paediatric doseNot recommended for vertigo
Adverse effectsSedation, amnesia, ataxia, dependence with repeated courses; falls in the elderly
ContraindicationsRespiratory insufficiency, sleep apnoea, myasthenia gravis; caution in elderly
InteractionsAdditive sedation with alcohol, opioids, other sedating anti-vertigo drugs
Patient advice / monitoringDays, not weeks — habituation and falls are the cost; no alcohol; no driving while sedated; do not save tablets for "next time" without review

Scopolamine (hyoscine, transdermal anticholinergic)

Scroll the table sideways on a smaller screen.

Scopolamine (hyoscine) — muscarinic antagonist
MechanismBlocks muscarinic receptors in vestibular pathways and the vomiting centre — one of the most effective agents for motion sickness
IndicationsMotion sickness prophylaxis (travel, sea sickness); less used for spontaneous vertigo
Adult doseTransdermal patch 1 mg applied behind the ear every 72 hours (apply ≥4 hours before travel); oral 0.3–0.6 mg
Paediatric dose<10 years: not recommended (patch); children are especially susceptible to anticholinergic toxicity
Adverse effectsDry mouth, blurred vision, drowsiness, confusion, urinary retention; dilated pupils if the drug transfers to the eye via fingers
ContraindicationsNarrow-angle glaucoma, prostatism/urinary retention, myasthenia gravis; caution in elderly
InteractionsAdditive anticholinergic burden with antihistamines, TCAs, antipsychotics; alcohol adds sedation
Patient advice / monitoringWash hands after applying; avoid touching eyes; remove the patch if eye pain or haloes appear (acute glaucoma); expect dry mouth

7 Cause-Specific Treatment

Scroll the table sideways on a smaller screen.

DiagnosisPrimary treatmentDrug role
BPPVEpley (posterior canal) repositioning maneuver — highly effective, first-lineMinimal — short course meclizine/cinnarizine for severe episodes or while awaiting repositioning; antiemetics for nausea
Vestibular neuritisEarly mobilisation; corticosteroids in severe acute lossShort (3–5 day) suppressant course (meclizine/cinnarizine ± prochlorperazine); stop early to allow compensation
LabyrinthitisTreat infection if bacterial; supportAs neuritis; longer symptom course possible
Ménière's diseaseLow-salt diet ± diuretic; betahistine maintenance; ENT follow-upMeclizine/promethazine or benzodiazepine for acute attacks; betahistine for recurrence
Vestibular migraineMigraine prophylaxis (propranolol, topiramate, amitriptyline)Acute suppressants as needed
Central vertigoTreat the cause — stroke pathway, imagingSuppressants give only partial, temporary relief

8 Rational Use & Duration

  • Short courses — vestibular suppressants for days, not months: acute neuritis 3–5 days, Ménière attacks as needed. Chronic use inhibits compensation and prolongs dizziness, causes falls and cognitive slowing, and masks treatable causes.
  • BPPV = maneuver, not medicine — medications do not reposition otoliths; treating BPPV with pills alone is the commonest irrational use of these drugs.
  • Add non-drug measures — treat the cause, review culprit drugs (antihypertensives, aminoglycosides, loop diuretics cause ototoxicity), hydrate, and start vestibular rehabilitation early.
  • Reassess persistent symptoms — vertigo beyond 2–3 weeks, recurrent episodes, or hearing change warrants audiometry, vestibular testing and ENT/neurology review.

9 Safety in Special Groups

  • Elderly — anticholinergic and sedative burden: falls, confusion, urinary retention, constipation; use the lowest dose for the shortest time; prefer ondansetron for nausea when sedation must be avoided.
  • Glaucoma, prostatism, asthma — avoid or use great caution with anticholinergics (scopolamine, promethazine).
  • Pregnancy — meclizine is the drug of choice for nausea/vertigo in pregnancy; promethazine also used; avoid benzodiazepines where possible.
  • Parkinson disease — avoid metoclopramide and prochlorperazine (dopamine blockade); prefer ondansetron.
  • Driving & machinery — all suppressants impair; counsel patients until compensation and off sedation.

10 Vestibular Rehabilitation

Compensation is experience-dependent: graded exposure to the movements that provoke dizziness retrains the vestibulo-ocular and vestibulospinal reflexes. Components include gaze-stabilisation exercises (VOR adaptation), habituation exercises for provoking movements, and balance/gait training (e.g. Cawthorne–Cooksey exercises). It is indicated after neuritis/labyrinthitis, for residual dizziness post-BPPV, in the elderly with fall risk, and as maintenance in chronic unilateral vestibular loss — and it works best when suppressant drugs have been stopped.

11 Viva & Exam Points

  • First-line suppressant — meclizine (H1 + anticholinergic at vestibular nuclei); 25–100 mg/day.
  • Betahistine — H3 antagonist; facilitates compensation; Ménière's maintenance 16 mg tds.
  • Duration discipline — suppressants for days; chronic use blocks compensation.
  • BPPV — Epley maneuver first; drugs are adjuncts only.
  • Nystagmus — peripheral: unidirectional, fatigable, fixation-inhibited; central: red flags for stroke.
  • Safety — anticholinergics in glaucoma/prostatism; phenothiazines in Parkinson disease; meclizine in pregnancy.

12 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top